679 related articles for article (PubMed ID: 33925883)
1. The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia.
Lato MW; Przysucha A; Grosman S; Zawitkowska J; Lejman M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925883
[TBL] [Abstract][Full Text] [Related]
2. An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia.
Patel J; Gao X; Wang H
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108359
[TBL] [Abstract][Full Text] [Related]
3. Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia.
Pocock R; Farah N; Richardson SE; Mansour MR
Br J Haematol; 2021 Jul; 194(1):28-43. PubMed ID: 33942287
[TBL] [Abstract][Full Text] [Related]
4. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
Dyakonova YY; Bydanov OI; Popov AM; Olshanskaya YV; Boichenko EG; Aleynikova OV; Maschan MA; Shelikhova LN; Litvinov DV; Khachatryan LA; Ponomareva NI; Fechina LG; Novichkova GA; Pashanov ED; Karachunskiy AI
Ter Arkh; 2018 Aug; 90(7):38-50. PubMed ID: 30701921
[TBL] [Abstract][Full Text] [Related]
5. Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors.
Diamanti P; Ede BC; Dace PE; Barendt WJ; Cox CV; Hancock JP; Moppett JP; Blair A
Br J Haematol; 2021 Feb; 192(3):577-588. PubMed ID: 32452017
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.
Kong J; Chen N; Li M; Zhang J; Wu X; Zong L; Wu D; Song B; Qiu H
Ann Hematol; 2022 Mar; 101(3):697-699. PubMed ID: 33954816
[No Abstract] [Full Text] [Related]
7. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.
Arora S; Vachhani P; Bachiashvili K; Jamy O
Leuk Lymphoma; 2021 Sep; 62(9):2292-2294. PubMed ID: 33691573
[No Abstract] [Full Text] [Related]
9. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
10. SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma.
Summers RJ; Teachey DT
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):718-725. PubMed ID: 35941070
[TBL] [Abstract][Full Text] [Related]
11. T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development.
Thomas X
Expert Opin Investig Drugs; 2023 Jan; 32(1):37-52. PubMed ID: 36541671
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature.
Grunenberg A; Sala E; Kapp-Schwoerer S; Viardot A
Expert Opin Pharmacother; 2022 Apr; 23(5):561-571. PubMed ID: 35193450
[TBL] [Abstract][Full Text] [Related]
14. Relapsed T Cell ALL: Current Approaches and New Directions.
McMahon CM; Luger SM
Curr Hematol Malig Rep; 2019 Apr; 14(2):83-93. PubMed ID: 30880359
[TBL] [Abstract][Full Text] [Related]
15. How I treat pediatric acute myeloid leukemia.
Rubnitz JE; Kaspers GJL
Blood; 2021 Sep; 138(12):1009-1018. PubMed ID: 34115839
[TBL] [Abstract][Full Text] [Related]
16. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.
Chonghaile TN; Roderick JE; Glenfield C; Ryan J; Sallan SE; Silverman LB; Loh ML; Hunger SP; Wood B; DeAngelo DJ; Stone R; Harris M; Gutierrez A; Kelliher MA; Letai A
Cancer Discov; 2014 Sep; 4(9):1074-87. PubMed ID: 24994123
[TBL] [Abstract][Full Text] [Related]
17. CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration.
Walker KL; Rinella SP; Hess NJ; Turicek DP; Kabakov SA; Zhu F; Bouchlaka MN; Olson SL; Cho MM; Quamine AE; Feils AS; Gavcovich TB; Rui L; Capitini CM
Leuk Lymphoma; 2021 May; 62(5):1167-1177. PubMed ID: 33843403
[TBL] [Abstract][Full Text] [Related]
18. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.
Peirs S; Matthijssens F; Goossens S; Van de Walle I; Ruggero K; de Bock CE; Degryse S; Canté-Barrett K; Briot D; Clappier E; Lammens T; De Moerloose B; Benoit Y; Poppe B; Meijerink JP; Cools J; Soulier J; Rabbitts TH; Taghon T; Speleman F; Van Vlierberghe P
Blood; 2014 Dec; 124(25):3738-47. PubMed ID: 25301704
[TBL] [Abstract][Full Text] [Related]
19. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
[TBL] [Abstract][Full Text] [Related]
20. Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia.
Ma M; Wang X; Tang J; Xue H; Chen J; Pan C; Jiang H; Shen S
Front Med; 2012 Dec; 6(4):416-20. PubMed ID: 23065427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]